XML 28 R50.htm IDEA: XBRL DOCUMENT v2.4.1.9

Collaborative Research Development and License Agreements - Additional Information (Detail) (USD $)	0 Months Ended	3 Months Ended		12 Months Ended		1 Months Ended	3 Months Ended		1 Months Ended		12 Months Ended		1 Months Ended
	Aug. 31, 2014 Workers	Dec. 31, 2014	Mar. 31, 2014	Dec. 31, 2014	Dec. 31, 2011	Dec. 31, 2008	Dec. 31, 2012	Mar. 31, 2012	Oct. 31, 2011	Sep. 30, 2006	Dec. 31, 2013	Dec. 31, 2012	Sep. 30, 2008	Sep. 30, 2013	Jun. 30, 2012	May 31, 2012	Jul. 31, 2011	Aug. 31, 2010
Deferred Revenue Arrangement [Line Items]
Number of healthy workers placebo was delivered by inhalation	45dvax_NumberOfHealthyWorkersPlaceboWasDeliveredByInhalation
Description of doses well tolerated				15.4 mg/week
Additional revenue recognized				$ 1,100,000us-gaap_DeferredRevenueRevenueRecognized
Revenue from milestone payment		8,000,000us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized	5,400,000us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized		3,000,000us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized
Deferred revenue											2,500,000us-gaap_DeferredRevenue
National Institutes Of Health
Deferred Revenue Arrangement [Line Items]
Grants receivable	200,000us-gaap_GrantsReceivable / us-gaap_TypeOfArrangementAxis = dvax_NationalInstitutesOfHealthMember
Glaxo Smith Kline
Deferred Revenue Arrangement [Line Items]
Collaboration Revenue						10,000,000us-gaap_ProceedsFromCollaborators / us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis = dvax_GlaxoSmithKlineMember
Hepatic Fibrosis and Cirrhosis | National Institutes Of Health
Deferred Revenue Arrangement [Line Items]
Grants receivable														200,000us-gaap_GrantsReceivable / us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis = dvax_HepaticFibrosisAndCirrhosisMember / us-gaap_TypeOfArrangementAxis = dvax_NationalInstitutesOfHealthMember
Autoimmune Disease | National Institutes Of Health
Deferred Revenue Arrangement [Line Items]
Grants receivable															600,000us-gaap_GrantsReceivable / us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis = dvax_AutoimmuneDiseaseMember / us-gaap_TypeOfArrangementAxis = dvax_NationalInstitutesOfHealthMember
Rheumatoid Arthritis | National Institutes Of Health
Deferred Revenue Arrangement [Line Items]
Grants receivable																400,000us-gaap_GrantsReceivable / us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis = dvax_RheumatoidArthritisMember / us-gaap_TypeOfArrangementAxis = dvax_NationalInstitutesOfHealthMember
Skin Autoimmune Inflammation | National Institutes Of Health
Deferred Revenue Arrangement [Line Items]
Grants receivable																	600,000us-gaap_GrantsReceivable / us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis = dvax_SkinAutoimmuneInflammationMember / us-gaap_TypeOfArrangementAxis = dvax_NationalInstitutesOfHealthMember
Amendment
Deferred Revenue Arrangement [Line Items]
Collaboration Revenue		8,000,000us-gaap_ProceedsFromCollaborators / us-gaap_StatementScenarioAxis = dvax_AmendmentMember	5,400,000us-gaap_ProceedsFromCollaborators / us-gaap_StatementScenarioAxis = dvax_AmendmentMember
Amendment | Maximum
Deferred Revenue Arrangement [Line Items]
Additional revenue recognized				100,000,000us-gaap_DeferredRevenueRevenueRecognized / us-gaap_RangeAxis = us-gaap_MaximumMember / us-gaap_StatementScenarioAxis = dvax_AmendmentMember
Amendment | Advance the program following completion of Phase 2a
Deferred Revenue Arrangement [Line Items]
Collaboration Revenue							6,000,000us-gaap_ProceedsFromCollaborators / us-gaap_ContingentConsiderationByTypeAxis = dvax_ContingentConsiderationMember / us-gaap_StatementScenarioAxis = dvax_AmendmentMember	2,600,000us-gaap_ProceedsFromCollaborators / us-gaap_ContingentConsiderationByTypeAxis = dvax_ContingentConsiderationMember / us-gaap_StatementScenarioAxis = dvax_AmendmentMember
Astra Zeneca
Deferred Revenue Arrangement [Line Items]
Research collaboration and license agreement period										3 years
Collaboration Revenue									3,000,000us-gaap_ProceedsFromCollaborators / us-gaap_CounterpartyNameAxis = dvax_AstraZenecaMember
Deferred revenue recognition period		30 months	48 months		74 months
Revenue from milestone payment				2,174,000us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized / us-gaap_CounterpartyNameAxis = dvax_AstraZenecaMember							2,507,000us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized / us-gaap_CounterpartyNameAxis = dvax_AstraZenecaMember	2,462,000us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized / us-gaap_CounterpartyNameAxis = dvax_AstraZenecaMember
Deferred revenue		12,800,000us-gaap_DeferredRevenue / us-gaap_CounterpartyNameAxis = dvax_AstraZenecaMember		12,800,000us-gaap_DeferredRevenue / us-gaap_CounterpartyNameAxis = dvax_AstraZenecaMember							4,800,000us-gaap_DeferredRevenue / us-gaap_CounterpartyNameAxis = dvax_AstraZenecaMember
National Institute Of Allergy And Infectious Diseases | Hepatitis B Virus
Deferred Revenue Arrangement [Line Items]
Grants receivable																		1,400,000us-gaap_GrantsReceivable / us-gaap_CounterpartyNameAxis = dvax_NationalInstituteOfAllergyAndInfectiousDiseasesMember / us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis = dvax_HepatitisBVirusMember
National Institute Of Allergy And Infectious Diseases | Iss Technology
Deferred Revenue Arrangement [Line Items]
Research collaboration and license agreement period													5 years
Grants receivable													$ 17,000,000us-gaap_GrantsReceivable / us-gaap_CounterpartyNameAxis = dvax_NationalInstituteOfAllergyAndInfectiousDiseasesMember / us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis = dvax_IssTechnologyMember

X

- Definition

Description of doses well tolerated.

+ References

No definition available.

+ Details

Name:	dvax_DescriptionOfDosesWellTolerated
Namespace Prefix:	dvax_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Number of healthy workers placebo was delivered by inhalation.

+ References

No definition available.

+ Details

Name:	dvax_NumberOfHealthyWorkersPlaceboWasDeliveredByInhalation
Namespace Prefix:	dvax_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Research collaboration and license agreement period.

+ References

No definition available.

+ Details

Name:	dvax_ResearchCollaborationAndLicenseAgreementPeriod
Namespace Prefix:	dvax_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Revenue recognition period.

+ References

No definition available.

+ Details

Name:	dvax_RevenueRecognitionPeriod
Namespace Prefix:	dvax_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Amount of deferred revenue as of balance sheet date. Deferred revenue represents collections of cash or other assets related to a revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 13

-Section A



Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 605

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SAB TOPIC 13.A.4(a).Q1 Response)

-URI http://asc.fasb.org/extlink&oid=27012821&loc=d3e214044-122780

+ Details

Name:	us-gaap_DeferredRevenue
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

X

- Details

Name:	us-gaap_DeferredRevenueArrangementLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Amount of previously reported deferred or unearned revenue that was recognized as revenue during the period. Deferred revenue is a liability related to a revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 605

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SAB TOPIC 13.A.4(a).Q1)

-URI http://asc.fasb.org/extlink&oid=27012821&loc=d3e214044-122780



Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 13

-Section A

+ Details

Name:	us-gaap_DeferredRevenueRevenueRecognized
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

X

- Definition

Carrying amount as of the balance sheet date of amounts due under the terms of governmental, corporate, or foundation grants.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.8)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682



Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 8

-Article 5

+ Details

Name:	us-gaap_GrantsReceivable
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

X

- Definition

Cash received from collaborators during the current period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 25

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3536-108585

+ Details

Name:	us-gaap_ProceedsFromCollaborators
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

X

- Definition

The amount of consideration recognized during the period for the milestone or milestones.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 605

-SubTopic 28

-Section 50

-Paragraph 2

-Subparagraph (e)

-URI http://asc.fasb.org/extlink&oid=19771982&loc=SL6892177-166501

+ Details

Name:	us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Details

Name:	us-gaap_CounterpartyNameAxis=dvax_AstraZenecaMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_CounterpartyNameAxis=dvax_NationalInstituteOfAllergyAndInfectiousDiseasesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=dvax_AutoimmuneDiseaseMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=dvax_GlaxoSmithKlineMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=dvax_HepaticFibrosisAndCirrhosisMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=dvax_RheumatoidArthritisMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=dvax_SkinAutoimmuneInflammationMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_StatementScenarioAxis=dvax_AmendmentMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_TypeOfArrangementAxis=dvax_NationalInstitutesOfHealthMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type: